GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shanghai HeartCare Medical Technology Corp Ltd (HKSE:06609) » Definitions » Cash And Cash Equivalents

Shanghai HeartCare Medical Technology (HKSE:06609) Cash And Cash Equivalents : HK$680.6 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai HeartCare Medical Technology Cash And Cash Equivalents?

Shanghai HeartCare Medical Technology's quarterly cash and cash equivalents declined from Dec. 2022 (HK$971.68 Mil) to Jun. 2023 (HK$759.69 Mil) but then stayed the same from Jun. 2023 (HK$759.69 Mil) to Dec. 2023 (HK$680.56 Mil).

Shanghai HeartCare Medical Technology's annual cash and cash equivalents declined from Dec. 2021 (HK$1,491.06 Mil) to Dec. 2022 (HK$971.68 Mil) and declined from Dec. 2022 (HK$971.68 Mil) to Dec. 2023 (HK$680.56 Mil).


Shanghai HeartCare Medical Technology Cash And Cash Equivalents Historical Data

The historical data trend for Shanghai HeartCare Medical Technology's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai HeartCare Medical Technology Cash And Cash Equivalents Chart

Shanghai HeartCare Medical Technology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
28.43 749.69 1,491.06 971.68 680.56

Shanghai HeartCare Medical Technology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only 1,491.06 1,168.63 971.68 759.69 680.56

Shanghai HeartCare Medical Technology Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Shanghai HeartCare Medical Technology  (HKSE:06609) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Shanghai HeartCare Medical Technology Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Shanghai HeartCare Medical Technology's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai HeartCare Medical Technology (HKSE:06609) Business Description

Traded in Other Exchanges
N/A
Address
No. 356, Zhengbo Road, Floor 1 and 3, Building 38, Pilot Free Trade Zone, Lingang New District, Shanghai, CHN
Shanghai HeartCare Medical Technology Corp Ltd is an innovative neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. Geographically, the Group's revenue is derived from Mainland China.
Executives
Ding Kui 2201 Interest of corporation controlled by you
Wisary Limited 2101 Beneficial owner
Wang Guohui
Shanghai Zandaqian Enterprise Management Consulting Center
Lyfe Capital Management Limited
Lyfe Capital Fund Iii (dragon), L.p.
Shanghai Weiyun Enterprise Management Consulting Partnership (lp)
Lyfe Columbia River Limited
Temasek Holdings (private) Limited
Elbrus Investments Pte. Ltd.
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited

Shanghai HeartCare Medical Technology (HKSE:06609) Headlines

No Headlines